



Wolfgang Aulitzky, MD is the Medical Director of the American Austrian Foundation. He is Associate Dean for International Medicine and Distance Learning, Adjunct Prof. of Clinical Urology and Adjunct Prof. of Clinical Reproductive Medicine at the Weill Medical College of Cornell University/New York Presbyterian Hospital. In 2016, he was appointed Adjunct Professor of Pediatrics in the Associated Faculty of the Perelman School of Medicine at the Children's Hospital of Philadelphia. He is also Associate Prof. of Urology at the Medical University of Innsbruck and Visiting Professor at the Medical University of Vienna. Amongst others he is a member of the American, German and Austrian Societies of Urology and was awarded the Zuckerkandlpreis of the Austrian Society of Urology in 1989. In 1995 he received the Silver Medal, in 2007 the Golden Medal for Merits to the Republic of Austria and in 2014 the cross of honor of the Land Salzburg. As Director of the Medical Program of the American Austrian Foundation he has initiated the Open Medical Institute, a scientific and educational collaboration of Weill Cornell and the New York Presbyterian Hospital, the Children Hospital of Philadelphia, Duke University, Columbia University, the Cleveland Clinic and leading hospitals in Austria. Dr. Aulitzky earned his medical degree at the University of Innsbruck in 1977, was a research associate at the University of Uppsala, Sweden and the Rockefeller University, New York. He received his training as an urologist at the University of Innsbruck and the General Hospital of Salzburg. He is the author of more than 140 publications on Urology, Andrology and Health Care issues and is co-author of books on basic and clinical urology/andrology.

Wolfgang Aulitzky, MD

Director, Open Medical Institute
American Austrian Foundation

Associate Dean and Gerhard Andlinger Professor
for International Medicine & Distance Learning
Adjunct Professor of Clinical Urology
Adjunct Professor of Clinical Reproductive Medicine
Weill Medical College of Cornell University

Adjunct Professor of Pediatrics
Perelman School of Medicine at the Children's Hospital of Philadelphia

Associate Professor of Urology
Medical University of Innsbruck, Austria

Kärntner Straße 51/II/Top 4
1010 Vienna
Austria

Phone: +43-1-533-8658
Fax: +43-1-533-8658-10
Email: w.aulitzky@openmedicalinstitute.org



Christopher Chapple, BSc, MBBS, MD, FRCS (Urol), FEBU, DHC is a Consultant Urological Surgeon at Sheffield Teaching Hospitals, Honorary Professor at University of Sheffield and Visiting Professor at Sheffield Hallam University. He has a particular interest in functional reconstruction of the lower urinary tract and the underlying pharmacological control mechanisms, and provides a tertiary service in lower urinary tract reconstructive surgery. He trained at the Middlesex Hospital where he completed his doctorate thesis. He continued there and the Institute of Urology in London for his sub-specialist training. He is Secretary General of the European Association of Urology, having previously been Chairman of the International Relations Committee, Adjunct Secretary General Responsible for Education, and Director of the European School of Urology. He was editor-in-chief of the journal *Neurourology and Urodynamics* from 2006-2016 and is on the editorial board of several international journals. He is an active member of many urological associations and societies including the British Association of Urological Surgeons, the European Association of Urology, the International Continence Society, the Association of Academic European Urologists and the American Association of Genitourinary Surgeons. He has chaired a number of guidelines initiatives including the NICE Guidelines Development Group on male LUTS and was co-chairman of the ICUD consultation on male LUTS. BAUS awarded him the St Peter's medal 2011 and SUFU awarded him the Lifetime Achievement Award in 2015. Prof. Chapple has co-authored 700+ articles, comments and letters in peer-reviewed journals and has written several chapters and books.

Christopher Chapple, BSc, MBBS, MD, FRCS (Urol), FEBU, DHC

Department of Urology
Sheffield Teaching Hospitals NHS Foundation Trust
Royal Hallamshire Hospital
Glossop Road
Sheffield, S10 2JF
United Kingdom

Phone: +44-(0)-114-271-3048
Email: c.r.chapple@sheffield.ac.uk



Douglas S. Scherr, MD is currently a Professor of Urology and Clinical Director of Urologic Oncology at the Weill Medical College of Cornell University. Dr. Scherr began his education at Cornell University where he received a B.A. in Government. Following this, he completed his medical school training at The George Washington University School of Medicine. Dr. Scherr then came to NY to complete his urologic residency at The New York Hospital-Cornell Medical Center. This was followed by a two-year fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center under the tutelage of Dr. Peter Scardino. Dr. Scherr currently focuses his practice on urological malignancies, and in particular, he has developed a busy robotic oncology service in the treatment of clinically localized prostate and bladder cancer. In addition, Dr. Scherr has an active basic science research laboratory in which he focuses on the molecular and genetic basis of prostate cancer.

Douglas S. Scherr, MD
Professor of Urology, Clinical Dir., Urologic Oncology
Weill Medical College of Cornell University
525 E. 68th St. Starr 900
New York, NY 10021
USA

Phone: +1-212-7465788
Email: dss2001@med.cornell.edu



Gero Kramer, MD is a urologist who specializes in uro-oncology and benign prostate hyperplasia. He grew up in Salzburg, Austria, and graduated from Medical School at the University of Vienna. He completed his postgraduate training program in urology in 1998 and was certified by the European Board of Urology in 1999. He is staff member at the Department of Urology of the Medical University of Vienna and since 2004 in the position of an Associate Professor. Since 1999 he is head of the Oncology Outpatient Clinic and since 2003 head of the Urology Research Lab. From 2005-2009 he chaired the Ludwig Boltzmann Cluster of Urology at the University of Vienna. He has worked extensively in the fields of immunology with a special focus on the alterations of the immune system of the ageing prostate and its relation to prostate cancer. He is actively involved in basic and clinical research of advanced prostate cancer and other urological tumors.

Gero Kramer, MD
Professor of Urology
Department of Urology
Medical University of Vienna
Waehringer Guertel 18-20
1090 Vienna
Austria

Phone: +43-1-4040026160
Email: gero.kramer@meduniwien.ac.at



Joan Palou Redorta, MD, PhD is a world-renowned expert in bladder cancer and in uro-oncology. He graduated from the Medical School of the Universitat Autònoma de Barcelona and became a urologist at the Hospital Vall d'Hebrón in Barcelona. He also spent some short periods in different centers in the USA during his residency training. He is an Associate Professor of Urology at the Universitat Autònoma de Barcelona (Spain) and Chairman of the Department at the famous Fundació Puigvert in Barcelona. Dr. Palou is Chairman of the European School of Urology. In 2016, he became a member of the American Association of Genito-Urinary Surgeons (AAGUS). He is, among many others, member of the Spanish Urological Association, European Association of Urology (EAU), American Urological Association and Société Internationale d'Urologie. Dr. Palou is an expert in laparoscopy and robotic surgery belonging to a cooperative group in robotic radical cystectomy. He has collaborated with the International Consultation on Bladder Cancer, Upper tract and Penile Cancer, sponsored by the WHO and SIU. Most importantly, he has been involved in writing the EAU Guidelines for non-muscle invasive bladder cancer and upper urinary tract tumors. Dr. Palou has published many chapters in medical and urology books and more than 200 publications in peer-reviewed journals. His recent publications focus mainly on bladder cancer studying the different aspects such as prognostic factors, BCG, T1G2 tumors, T1G3 tumors, guidelines, risk stratification or robotic surgery. Some new protein markers of aggressiveness and prognosis of progression in patients with T1G3 tumors of the bladder has been developed with the CNIO (National Center for Oncologic Investigations), Columbia University and with other European centers with encouraging results. He is also a referee of several national and international journals. He has given countless lectures in national and international meetings and as a visiting professor in University Hospitals all over the world. His group has received several awards for publications, videos, oral and poster presentations at different meetings. The most known is the Hans Marberger prize in 2004.

Joan Palou Redorta, MD, PhD
Chairman of Urology Department
Associate Professor of Urology
Director of European School of Urology
Fundació Puigvert
Universitat Autònoma de Barcelona
Cartagena 340
08025 Barcelona
Spain

Phone: +34-93-4169700
Email: jpalou@fundacio-puigvert.es



Shahrokh F. Shariat, MD is currently a Professor and Chairman of the Department of Urology, at the Medical University of Vienna, Vienna General Hospital in Vienna, Austria. He is also adjunct professor of urology and medical oncology at the Weill Cornell Medical Center in New York, NY, adjunct professor of urology at the University of Texas Southwestern Medical Center in Dallas, TX, USA, and guest professor at the Faculty of Medicine, Charles University in Prague, CZ. He has published more than 950 peer-reviewed research papers (Scopus h-index 85, 25693 citations; Google scholar h-index 109, 605835 citations), >1.000 non-peer-reviewed papers, and 18 book chapters. He is the holder of four patents stemming from his research in prostate and bladder cancer, and is the recipient of various national and international rewards. He has, for example, received the prestigious Matula Award from the European Urological Association and the Gold Cystoscope 2017 from the American Urological Association. He is currently spearheading several collaborative multicenter groups (Bladder Cancer Research Consortium, The Bladder Cancer Detection Group, and The Upper Tract Urothelial Carcinoma Collaboration) and prospective clinical trials. He is a member of various academic societies and a journal, meeting abstract, and grant reviewer for numerous national and international organizations. He is an editorial board member of various journals including *European Urology*, *BJU International*, *World Journal of Urology*, *Current Opinion in Urology* (editor in chief), and *Immunotherapy*, among others. He heads a medical charity for refugees and is on the medical advisory board for two other charities. His research focuses on urologic oncology - molecular mechanisms, markers, early detection, natural history, treatment, and translational and outcomes research. Specially, Dr. Shariat has been working on the discovery, testing and validation of molecular markers associated with the biological and clinical behavior of prostate and urothelial cancers. His laboratory research focuses on integrative genomics and epigenomics of urothelial carcinoma with the goal of designing personalized therapeutic strategies.

Shahrokh F. Shariat, MD
Professor
Department of Urology
Medical University of Vienna
Chairman
Comprehensive Cancer Center
Vienna General Hospital
Waehringer Guertel 18-20
1090 Vienna
Austria

Adjunct Professor of Urology and Medical Oncology
Weill Cornell Medical Center
New York, NY
USA

Adjunct Professor of Urology
University of Texas Southwestern Medical Center
Dallas, TX
USA

Guest Professor
Faculty of Medicine
Charles University
Prague
CZ

Phone: +43-1-40400-26150
Email: shahrokh.shariat@meduniwien.ac.at
